Summary of Intellia Therapeutics Conference Call Company Overview - **Company**: Intellia Therapeutics (NasdaqGM: NTLA) - **Event**: 2026 Global Healthcare Conference - **Focus**: Discussion on pivotal data from the HAELO study and the company's gene editing product, Lonbo-Z Key Points Industry and Market Dynamics - **HAE Market**: The Hereditary Angioedema (HAE) market is large and growing, filled with premium products. The company anticipates a trend towards long-term prophylaxis (LTP) use and believes it has a competitive product in this space [12][13] - **Patient Needs**: HAE patients face significant challenges, including social, emotional, and financial burdens. The company aims to address these unmet needs with its product, which offers a potential for no attacks and no long-term therapy [12][13] Product Development and Data Expectations - **Pivotal Study**: The company is looking forward to the completion of its Phase 3 program for Halo, with top-line data expected mid-year. The focus will be on attack rate reductions and safety [5][6] - **Data Maturation**: The company expects to be competitive with existing therapies, aiming for better attack-free rates than the current market leader, which has a 45% attack-free rate reduction [6][11] Patient Adoption and Market Penetration - **Early Adopters**: The company anticipates that 20-25% of patients will be early adopters of the new therapy, with a significant portion of patients (75-80%) looking for alternatives to their current treatments [15][16] - **Community Engagement**: The HAE community is described as tight-knit and well-informed, which could facilitate the adoption of the new therapy through word-of-mouth and advocacy [17] Global Market Strategy - **International Expansion**: The company is focused on building operational capabilities to access markets outside the U.S., with potential collaborations or licensing arrangements being considered [19][20] Financial Considerations - **Cost of Goods and Pricing**: The company has not disclosed exact manufacturing costs but anticipates a gross margin in excess of 95% for Lonbo-Z. Current therapies in the HAE space cost around $650,000-$700,000 annually, which will inform pricing strategies [23][24] - **Market Potential**: The total addressable market for HAE is estimated to be $14 billion-$15 billion, depending on pricing strategies [56][57] Safety and Efficacy - **Safety Profile**: The company is confident in the safety profile of Lonbo-Z, with no significant liver function test (LFT) elevations observed in the HAE patient population [36][37] - **Durability of Treatment**: The expectation is that patients will experience a significant reduction in the need for long-term prophylaxis, leading to a decrease in overall healthcare costs [49][50] Future Outlook - **Market Durability**: The company believes that as it successfully treats patients, the number of eligible patients may decrease, but the market remains substantial due to the high prevalence of HAE [56][57] - **Long-term Vision**: The company aims to position itself as a leader in gene editing therapies, with a focus on providing durable, one-time treatments that significantly improve patient quality of life [39][40] Additional Insights - **Engagement with Payers**: The company has been proactive in discussions with payers to ensure smooth reimbursement processes upon product launch [43][45] - **Patient Education**: The company is committed to educating physicians and patients about the therapy's benefits and expected outcomes [51][52]

Financial Data and Key Metrics Changes - The company is advancing its lead development candidate, Edit 401, which has shown a 90% mean reduction in LDL cholesterol in preclinical studies, significantly outperforming current standard treatments that achieve 40% to 60% reductions [4][18]. - Edit 401 is positioned as a one-time treatment with the potential for lifelong LDL reduction and associated cardiovascular risk reduction, indicating a favorable business model aligned with typical biopharma margins [5][18]. Business Line Data and Key Metrics Changes - Edit 401 has been selected as the lead program due to its compelling preclinical data, which supports rapid progression to human proof of concept studies expected by the end of 2026 [5][19]. - The company is also focusing on optimizing candidates for its hematopoietic stem cell (HSC) program while advancing Edit 401 [19][20]. Market Data and Key Metrics Changes - The market potential for Edit 401 is substantial, with projections indicating that atherosclerotic cardiovascular disease will impose over $300 billion in national expenditures by 2035 in the U.S. alone [5]. - Hyperlipidemia affects over 70 million patients in the U.S., highlighting a significant patient population that could benefit from Edit 401 [6]. Company Strategy and Development Direction - The company aims to be a leader in in vivo gene editing by developing CRISPR-based medicines that are best in class or first in class therapeutics [3]. - The strategy involves a differentiated approach focusing on functional upregulation of gene expression rather than knockdown strategies, allowing the company to target areas others cannot [10]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Edit 401's potential to deliver meaningful benefits across multiple segments of the hyperlipidemia population, emphasizing the need for effective treatments in refractory patient segments [7][19]. - The company remains committed to advancing its pipeline and optimizing resources for its lead program while exploring other therapeutic areas [19][20]. Other Important Information - Edit 401 utilizes a proprietary CRISPR-Cas9 enzyme and dual guide RNAs, demonstrating a six-fold mean increase in LDLR protein levels, which is crucial for its efficacy [12][13]. - The company has established a strategic partnership with Genevant for LNP delivery, which has shown good tolerability in preclinical studies [13][100]. Q&A Session Summary Question: What patient populations will be targeted for Edit 401 testing? - The company plans to consider segments such as heterozygous familial hypercholesterolemia and other refractory patient populations, with final selections depending on regulatory discussions [24]. Question: Is there evidence that 90% LDL reduction leads to lower cardiovascular risk? - Management indicated that clinical trials show a 20% risk reduction for every 40 mg/dL lowering of LDL-C, with lower levels associated with even greater risk reductions [32][34]. Question: How will LDL reduction in mice translate to humans? - The company is optimistic about translatability, having observed consistent 90% reductions in both non-human primates and mice, projecting that human doses will be below 1 mg/kg [36]. Question: What is the expected market positioning for Edit 401? - Edit 401 is expected to serve severe patient populations, particularly those who do not achieve LDL targets with existing therapies, due to its significant efficacy and compliance advantages [42][44]. Question: What are the safety profiles observed in preclinical studies? - The company reported no thrombocytopenia and transient liver enzyme elevations that resolved within a week, indicating a favorable safety profile [110]. Question: Will there be a need for redosing in the future? - While the company has shown durability of LDL reduction for at least 12 weeks, they believe there is room for redosing if necessary [118][120]. Question: What are the expectations for future clinical trial requirements? - The company anticipates that different patient segments may have varying requirements determined by regulators, but expects to require a small population to detect the biological effect size in human studies [129].

Core Insights - Editas Medicine has nominated EDIT-401 as its lead in vivo development candidate, marking a significant milestone in its vision for programmable gene editing [2][3] - EDIT-401 is designed to treat hyperlipidemia by directly editing the LDLR gene, aiming for a substantial reduction in LDL cholesterol levels [3][5] - The company has a strong cash position, with $178.5 million in cash and equivalents, expected to fund operations into the second quarter of 2027 [9] Product Overview - EDIT-401 is an experimental gene editing medicine that targets the LDLR gene to increase LDLR protein expression, potentially offering a one-time treatment for lifelong benefits [3][7] - Preclinical studies in non-human primates have shown a ~90% mean reduction in LDL-C levels, compared to 40-60% reductions seen with standard therapies [7] - The targeted approach of EDIT-401 aims to address the significant unmet need in the hyperlipidemia patient population, which exceeds 70 million in the U.S. [4][7] Market Potential - Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death globally, with U.S. healthcare expenditures projected to exceed $300 billion by 2035 [4] - The company anticipates a sizeable market potential for EDIT-401, supported by favorable healthcare economics and a business model aligned with typical biopharma margins [7] Upcoming Milestones - Editas plans to submit an investigational new drug (IND) application for EDIT-401 by mid-2026, with the goal of achieving human proof-of-concept data by the end of 2026 [8] - The company expects to identify an additional target cell type or tissue by the end of 2025 [8]

Core Insights - Editas Medicine is focusing on becoming a premier in vivo gene editing company, particularly since the appointment of CEO Gilmore three years ago [4]. Group 1: Company Strategy - The company has generated exciting data in the field of in vivo gene editing, which they are eager to advance [4]. - Editas is refining its focus on in vivo development to address unmet needs in genetic disorders such as thalassemia and sickle cell disease [3][4]. Group 2: Market Landscape - There is significant potential in the treatment landscape for thalassemia and sickle cell, with current approved options having weaknesses that in vivo solutions could address [5].

Summary of Editas' Conference Call Company Overview - **Company**: Editas Medicine - **Industry**: Biotechnology, specifically focusing on gene editing and therapy Key Points and Arguments Focus on In Vivo Development - Editas aims to be a premier in vivo gene editing company, refining its focus since the CEO's arrival three years ago [5] - The company has generated promising data in in vivo gene editing, particularly for sickle cell disease, which is seen as a significant opportunity [6][7] Market Potential and Treatment Efficacy - In vivo gene editing is expected to expand the market and reduce patient burden compared to ex vivo therapies [6] - The company believes that the efficacy bar for in vivo treatments is on par or better than ex vivo options, allowing for a larger patient population [9] Preclinical Data and Optimization - Editas is applying learnings from its ex vivo program to optimize its in vivo gene editing approach, focusing on delivery mechanisms [10][11] - Proprietary TLNP technology is showing great potential in preclinical settings [11] Business Development and Pipeline Expansion - The company is exploring additional investments and partnerships to expand its pipeline, particularly in in vivo applications [13][17] - Editas is focused on being best-in-class in vivo gene therapy, with a strategic approach to target functional proteins [15][16] Financial Position and Capital Efficiency - Editas has a cash runway extending into Q2 2027, providing breathing room to advance its in vivo programs [19][21] - The company is being capital efficient, particularly in managing wind-down costs from previous programs [26] Licensing Agreements and Intellectual Property - Current licensing agreements remain unaffected by recent legal decisions, and Editas is open to new licensing opportunities [28][29] Upcoming Data and Milestones - Editas presented data at ASGCT, showing over 80% reduction in a disease biomarker in its liver program [32] - The company plans to declare two drug candidates by mid-2025 and file an IND for one candidate in 2026, with potential human proof of mechanism expected by late 2026 to early 2027 [36] Conclusion - Editas is focused on advancing its in vivo gene editing capabilities while maintaining a strong financial position and exploring new partnerships to enhance its pipeline [41]

Financial Data and Key Metrics Changes - As of March 31, 2025, the company's cash, cash equivalents, and marketable securities were approximately $707.1 million, down from $861.7 million as of December 31, 2024, reflecting normal operational expenses and nonrecurring costs associated with portfolio prioritization and workforce reduction [22][23] - Collaboration revenue for Q1 2025 was $16.6 million, compared to $28.9 million in Q1 2024, primarily due to a decrease in revenue under the Avansel license agreement [23] - R&D expenses were $108.4 million in Q1 2025, down from $111.8 million in Q1 2024, driven by lower employee-related expenses and stock-based compensation [24] Business Line Data and Key Metrics Changes - The company has dosed the first patient in its Phase 3 studies for hereditary angioedema (HAE) and hereditary ATTR with polyneuropathy, indicating significant progress in its clinical pipeline [7][14] - Enrollment in the global Phase 3 HALO study for HAE is progressing rapidly, confirming high unmet needs despite existing treatment options [8][15] - The FDA granted RMAT designation for NexSee for the treatment of ATTR with cardiomyopathy, which is expected to enhance engagement with the FDA [8][20] Market Data and Key Metrics Changes - The company is observing significant interest from both investigators and patients across its programs, with over 90 sites actively enrolling in the Phase 3 magnitude study for ATTR with cardiomyopathy [8][20] - The market for treatments for hereditary angioedema and ATTR amyloidosis is expanding, with increasing recognition of the diseases and improved diagnostic procedures [60] Company Strategy and Development Direction - The company is focused on operational excellence and aims to provide life-changing benefits through one-time therapies for severe diseases [6][7] - Intellia is building critical commercial foundations to bring its therapies to patients quickly, with a strong emphasis on evolving into a commercially ready company [9][10] - The company plans to file its first BLA in 2026 and is monitoring the regulatory environment closely, with no current changes affecting its timelines [12][13] Management's Comments on Operating Environment and Future Outlook - Management remains confident in meeting or exceeding regulatory timelines and objectives, with a strong relationship with the FDA [12][13] - The company is closely monitoring potential implications of pending pharmaceutical tariffs but is confident in its manufacturing and distribution capabilities [13] - Management expressed optimism about the potential of its therapies to reset treatment standards for patients with HAE and ATTR [14] Other Important Information - The company expects a year-over-year decline in GAAP operating expenses of 5% to 10% in 2025, with sufficient cash to fund operations into the first half of 2027 [25][36] - The company is undergoing a restructuring process aimed at reducing its real estate footprint and workforce, which is expected to yield significant cost savings [22][39] Q&A Session Summary Question: Update on magnitude Phase 3 trial enrollment and patient baseline characteristics - Management indicated that over 50% of patients in the study are expected to be on tafamidis, which is important for demonstrating the drug's benefit over existing treatments [30] Question: Cash burn and operating expenses expectations - The average cash use is estimated at $95 million per quarter for 2025 and 2026, with a focus on efficient operations and significant cost savings from real estate transactions [36][42] Question: Launch dynamics for the first in vivo gene editing therapy - The company is building a commercial organization with insights from prior one-time therapies, expecting efficient patient access post-approval [54][56] Question: Pricing strategy in light of competitive landscape - The company is focused on providing a competitive price for its one-time treatment, considering the significant cost savings for payers compared to chronic therapies [88][89] Question: Enrollment impact from new drugs in the market - Despite the approval of new drugs, the company has maintained brisk enrollment in its studies, with physicians seeing the potential for significant benefits from its therapies [95][96]